Leen Kawas is a seasoned biotechnology executive currently serving as Managing General Partner at Propel Bio Partners LLC since November 2021. Kawas is actively involved in the biotechnology space as a member of the board of directors for Inherent Biosciences, Inc. and Persephone Biosciences, and as a board observer at Tympanogen and NOWDiagnostics | NOWDx. Additional roles include mentorship at the Washington Innovation Network, membership in the Forbes Business Council, and advisory capacity at Nucleate. Previous experience includes leadership positions at Athira Pharma, where Kawas held the titles of CEO & President and Vice President of Research. Educational qualifications include a PhD in molecular pharmacology & toxicology from Washington State University and executive education from the Wharton School and the Foster School of Business.